Hikma gives US ‘skinny label’ generics stronger protection than in EU, practitioners say
The US Supreme Court’s Hikma Pharmaceuticals v. Amarin Pharma decision this year makes induced patent infringement claims against “skinny label” generic drugmakers harder to plead, practitioners say, contrasting the ruling with...To view the full article, register now.
Already a subscriber? Click here to view full article